Plexus Corp.

Plexus Corp. (PLXS) Market Cap

Plexus Corp. has a market capitalization of .

No quote data available.

CEO: Todd Kelsey

Sector: Technology

Industry: Hardware, Equipment & Parts

IPO Date: 1986-02-05

Website: https://www.plexus.com

Plexus Corp. (PLXS) - Company Information

Market Cap: -|Sector: Technology

Company Profile

Plexus Corp., together with its subsidiaries, provides electronic manufacturing services in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. It offers design and development, supply chain, new product introduction, and manufacturing solutions, as well as aftermarket services to companies in the healthcare/life sciences, industrial/commercial, aerospace/defense, and communications market sectors. Plexus Corp. was founded in 1979 and is headquartered in Neenah, Wisconsin.

Analyst Sentiment

77%
Strong Buy

From 5 Active Polls

1Y Forecast: $265.00

▲ +0.0% Potential Upside

Consensus Target Metrics

Low Bound

$195

Median

$278

High Bound

$310

Average

$265

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$265.00
▼ -2.93% Upside
Low Target
$195.00
-29% Risk
Median Target
$277.50
2% Mid
High Target
$310.00
14% Max

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

Sentiment volume allocation data unavailable.

Historical valuation matrix unavailable.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 PLEXUS CORP (PLXS) — Investment Overview

🧩 Business Model Overview

Plexus is an electronics manufacturing services (EMS) provider with a concentration in complex, regulated end markets—most notably healthcare/medical technology. The value chain spans design and engineering support (including design-for-manufacturability and New Product Introduction activities), procurement and kitting, and build-to-print and configurable manufacturing across advanced manufacturing processes. The company’s operating model typically blends:

  • Program-based lifecycle work (from early NPI through volume production)
  • Ongoing production runs driven by device lifecycle needs and customer demand
  • Quality and compliance execution tailored to regulated product requirements

Customer stickiness is reinforced by engineering qualification, process validation, documentation/traceability, and the operational friction associated with switching an approved manufacturing source—particularly in medical-device-adjacent production environments.

💰 Revenue Streams & Monetisation Model

Revenue is primarily generated through manufacturing services and engineering-led program support. Monetisation typically comes from a mix of:

  • Manufacturing and assembly fees (labor, overhead absorption, and process-specific value-add)
  • Engineering and NPI services that often precede mass production and can improve long-term program economics
  • Pass-through or supply-chain-related components where revenue may move with procurement volumes, while gross margin depends on how much value Plexus retains versus how much is neutralized as pass-through

Margin drivers are largely tied to the mix of higher-complexity programs, the stability of utilization, the degree of procurement performance, and the extent of automation and process yield. In regulated end markets, disciplined quality systems can support defensible margins but also raise compliance and audit costs.

🧠 Competitive Advantages & Market Positioning

Plexus competes in a crowded EMS landscape, but its positioning is anchored by structural constraints that favor experienced providers in complex, qualification-heavy manufacturing. The primary moat characteristics include:

  • High Switching Costs (Program Qualification): Customers face technical, regulatory, and schedule risk when qualifying a new manufacturing partner—often requiring revalidation, documentation transfer, and process re-verification.
  • Regulatory/Quality Execution Capability: In healthcare-linked production, quality management systems and traceability requirements create a high bar that is difficult to replicate quickly.
  • Embedded Engineering Knowledge: Engineering support during NPI can become operationally integrated into production, reducing friction and improving yield over a program lifecycle.

Competitive benchmarking (industry peers):

  • Sanmina (SANM) and Jabil (JBL): large-scale diversified EMS providers that pursue broad end markets. Their scale can be a cost advantage, but switching dynamics can still favor qualified partners on complex, regulated programs where documentation and validation matter.
  • Benchmark Electronics (BHE) and Celestica (CLS): similarly positioned providers with focus on electronics manufacturing and engineering services. Plexus differentiates through emphasis on complexity and regulated execution where qualification and process discipline drive stickiness.

In contrast to large, generalist EMS peers that optimize for scale breadth, Plexus’ emphasis on program depth and quality-intensive environments increases the durability of customer relationships and supports more stable economics across manufacturing ramps and production transitions.

🚀 Multi-Year Growth Drivers

Over a five- to ten-year horizon, growth is supported by structural outsourcing and product complexity trends:

  • Outsourcing of manufacturing to qualified partners: OEMs increasingly rely on EMS providers for engineering support, scale execution, and supply-chain management.
  • Healthcare/medical technology product complexity: Devices and components often require meticulous process control, traceability, and validation—favoring suppliers with established quality systems.
  • Supply-chain localization and resilience: Longer-term reshoring/nearshoring programs tend to increase demand for regionally capable manufacturing providers with the ability to handle qualification and ramp execution.
  • Lifecycle services and program continuity: Once qualified, manufacturing relationships can extend across product generations, revisions, and sustaining demand.

TAM expansion is less about broad EMS volume growth and more about share capture in complex programs where qualification, compliance, and engineering integration create durable partner preference.

⚠ Risk Factors to Monitor

  • Customer program concentration and ramp risk: EMS economics can be sensitive to timing of NPI starts, volume ramps, and program cancellations.
  • Quality and compliance events: In regulated end markets, a quality escape or documentation deficiency can lead to remediation costs, customer action plans, and potential revenue disruption.
  • Technology and product mix shifts: Changes in component architecture or manufacturing process requirements can affect utilization and margin until new capacity and tooling are optimized.
  • Supply-chain volatility: Component availability and lead-time dynamics can drive working-capital needs and procurement costs.
  • Capital intensity of advanced capacity: Automation, test infrastructure, and compliant facilities require ongoing investment to remain competitive and meet customer requirements.

📊 Valuation & Market View

The market typically values EMS providers on an EV/EBITDA and EV/Revenue basis, with emphasis on:

  • Margin durability: the ability to sustain gross margin through mix shifts and yield performance
  • Revenue quality: recurring production share versus project-based volatility
  • Operating leverage: utilization and cost absorption dynamics as volumes fluctuate
  • Visibility: stability and credibility of program pipeline and customer qualification momentum

Multiple expansion or contraction generally reflects confidence in sustainable profitability rather than pure top-line growth.

🔍 Investment Takeaway

Plexus’ investment case rests on structural stickiness from qualification-driven switching costs and the operational discipline required to serve regulated, complex manufacturing programs. While the EMS sector faces cyclical end-market exposure and program execution risk, Plexus’ focus on engineering integration and quality-intensive production supports a more defensible relationship profile than providers competing primarily on commodity throughput.


⚠ AI-generated — informational only. Validate using filings before investing.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-04-04

"PLXS reported Q2 2026 revenue of $1.164B (+8.84% QoQ; +18.71% YoY) and net income of $49.8M (+20.92% QoQ; +27.54% YoY). EPS came in at $1.86 ($1.81 diluted), up from $1.54 in Q1 and $1.44 in Q2’25. Profitability improved: net margin expanded to 4.28% from 3.85% in the prior quarter and 3.99% a year ago; operating margin rose to 5.31% from 5.09% QoQ and 4.98% YoQ. Cash flow reporting is inconsistent/zeroed for the quarter, so cash-flow quality can’t be validated directly from Q2’26. However, balance sheet health remains solid: total assets increased to $3.36B (from $3.19B QoQ; $3.14B a year ago) and total equity is stable at $1.49B. Leverage is modest with net debt still negative (net debt improved to about -$43M vs -$29M QoQ and -$131M in Q4’25). There were no dividend or buyback cash flow entries in this quarter’s dataset. Shareholder returns are very strong with price up 87.53% over 1 year; that momentum meaningfully boosts total-return potential. Analyst consensus targets (~$222.5) sit slightly below the current price (~$228.64), implying the near-term setup is more about execution than valuation compression."

Revenue Growth

Strong

Q2’26 revenue rose 8.84% QoQ to $1.164B and 18.71% YoY, indicating accelerating top-line momentum across the last four quarters.

Profitability

Good

Margins expanded: net margin 4.28% in Q2’26 vs 3.85% QoQ and 3.99% YoY; EPS increased to $1.86 from $1.54 (QoQ) and $1.44 (YoY).

Cash Flow Quality

Fair

Q2’26 cash flow fields are reported as zero/incomplete, limiting confidence. Prior quarter CFO was negative (Q1’26), while Q4’25 and earlier showed positive CFO/FCF—directionally mixed.

Leverage & Balance Sheet

Good

Balance sheet strengthened: total assets up QoQ and YoY, equity stable around $1.49B, and net debt remains negative (improving versus recent quarters).

Shareholder Returns

Strong

Very strong 1-year price momentum (+87.53%). Dividend yield is shown as 0 and buybacks are not evidenced in Q2’26 cash-flow data, but capital appreciation is clearly dominant.

Analyst Sentiment & Valuation

Neutral

Consensus target (~$222.5) is modestly below the current price (~$228.64), suggesting valuation is not obviously cheap despite strong fundamentals.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

PLXS delivered a clear beat in Q2 2026 with revenue of $1.164B (+19% YoY) and non-GAAP EPS of $2.05, which exceeded the top end of guidance. Management attributed gross margin of 10.2% to favorable mix (services) and fixed-cost leverage, offsetting seasonal compensation and ramp-related pressures via ongoing productivity initiatives. The company also maintained strong capital discipline: $16M free cash flow, a 64-day cash cycle (5 days better sequentially), and continued buybacks ($20.6M in Q2; $42M remaining). The core bull case is accelerating program ramps and sustained share gains: record $355M annualized manufacturing wins across aerospace/defense, healthcare, and industrial, alongside funnel growth to $4B. For Q3, PLXS guided revenue $1.2B–$1.25B and non-GAAP operating margin 5.9%–6.3%. Risks are primarily supply chain component tightness (semis/passives/memory/PCB fabs) and near-term working capital investment pulling free cash flow into usage, but management framed these as forecasted and manageable with proactive sourcing and working-capital efficiency.

AI IconGrowth Catalysts

  • Record $355 million annualized new manufacturing program wins (30 new programs) driving mid-teens or greater FY2026 revenue growth
  • Aerospace and defense outperformance: Q2 revenue up 19% sequentially; Kelso, Scotland follow-on share gain wins and additional unmanned defense customer award
  • Semi-cap share gains amplifying market demand in industrial; industrial Q2 revenue up 12% sequentially and Q3 outlook low double-digit growth
  • Increasing breadth of customer interest and expanding funnel of qualified manufacturing opportunities (up 11% sequentially to $4 billion)

Business Development

  • Aerospace/Defense: Kelso, Scotland won follow-on share gain award from an existing defense customer; also a follow-on award from an existing unmanned defense customer (Boise, Idaho facility)
  • Healthcare/Life Sciences: Xiamen, China won a next-generation point-of-care ultrasound system; Neenah, Wisconsin won for a robotic surgical platform (seamless engineering to production transition)
  • Industrial: substantial award from an existing customer launching a new data center power solutions product line (Bangkok, Thailand facility)
  • Industrial: follow-on award from an existing robotics customer (Guadalajara, Mexico assembly); Guadalajara campus selected to support production of an energy storage system for electric commercial vehicles

AI IconFinancial Highlights

  • Q2 revenue $1.164B exceeded guidance; +19% YoY and fifth consecutive sequential revenue growth
  • Non-GAAP EPS $2.05 exceeded guidance (above top end); non-GAAP operating margin 6% at top end of guidance
  • Gross margin 10.2% at top end of guidance due to favorable mix (service offerings) and fixed cost leverage plus productivity offsets to seasonal compensation cost increases
  • Tax: favorable tax rate contributed to EPS outperformance; non-GAAP effective tax rate guided 16%–18% for Q3 and FY2026 (unchanged)
  • Cash flow: Q2 free cash flow $16M exceeded forecast (breakeven to slight cash usage)
  • Working capital: cash cycle 64 days, 5 days lower than last quarter; receivables improved 3 days, inventory improved 4 days, advanced payments reduced by 6 days with net $15M returned to customers

AI IconCapital Funding

  • Share repurchase: acquired ~109,000 shares for $20.6M in Q2; $42M remaining on current repurchase authorization
  • Liquidity: net cash position at quarter-end; $137M outstanding under revolving credit facility with over $350M available to borrow
  • FY2026 capex outlook: $100M–$120M
  • FY2026 free cash flow outlook: $50M–$75M

AI IconStrategy & Ops

  • Operational efficiency investments expanded to support program ramps and sustaining revenue momentum while still delivering margin at the top end
  • Throughput improvement: teams improved throughput of some assets by ~10% and avoided ~$20M of capital investments (last 6 months)
  • Working capital efficiency strategy: despite higher working capital investments in Q3, company targets low-60s cash cycle days exiting FY2026
  • Supply chain and sourcing process refinement: early identification of risk and consultative engagement with customers; proactive alternates planning and early PO horizon/placement

AI IconMarket Outlook

  • Q3 2026 guidance: revenue $1.2B–$1.25B (midpoint +5% sequential, +20% YoY)
  • Q3 2026 non-GAAP operating margin: 5.9%–6.3%
  • Q3 2026 non-GAAP EPS: $2.02–$2.18
  • Q3 2026 gross margin: 9.9%–10.2% (midpoint slightly below Q2 due to timing of program ramps/capability investments/higher incentive compensation)
  • FY2026 outlook: mid-teens or greater revenue growth; non-GAAP operating margin 6% or greater; working capital efficiency targeted to end FY2026 with cash cycle days in the low 60s

AI IconRisks & Headwinds

  • Margin headwind risk from program ramp timing and capability investments in Q3 (mitigated by productivity and fixed-cost leverage)
  • Supply chain tightening: allocation/tightening risk in portions of semiconductor (including passives/memory), raw PCB fabs; lead times extending for high-performance passives, magnetics, and some microcontrollers
  • Working capital utilization: Q3 free cash flow expected to be cash usage due to higher working capital investments to support accelerating revenue growth

Q&A: Analyst Interest

  • Topic: Cash cycle and long-term working capital investment tradeoffs: Management explained the company is in a low-to-mid 60s days range going forward and into fiscal '27, with approximately 10%–15% additional working-capital dollars per incremental revenue growth. David added that operational efficiency improved throughput ~10%, avoiding about $20M of capital investments, supporting similar revenue on a steadier capital base.
  • Topic: Industrial demand near-term sustainability from energy infrastructure and related edge/datacenter adjacencies: Oliver linked growth to energy infrastructure wins plus Boise facility regulatory compliance enabling nuclear power control systems. He extended the narrative to data center power platform opportunities (power management/storage/thermal/fluidics), and AI-at-the-edge ruggedized equipment needs, emphasizing a strong, active funnel for sustain/service and manufacturing execution.
  • Topic: Operating margin drivers and puts/takes across segments plus supply chain gating risk: Management said sector margin differentials are small given current market mix; ramping costs temporarily pressure margins while fixed-cost leverage and higher-margin sustaining services/engineering and automation benefits support 6%+ targets. On supply chain, they stated forecasts account for constraints, but highlighted tightened allocations in semiconductor portions, passives, memory, raw PCB fabs, and extended lead times, mitigated via early PO placement, alternates, and consultative customer engagement.

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the PLXS Q2 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
© 2026 Stock Market Info — Plexus Corp. (PLXS) Financial Profile